Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis

Nakamura, Yukio; Suzuki, Takehiko; Kamimura, Mikio; Ikegami, Shota; Uchiyama, Shigeharu; Kato, Hiroyuki

doi:10.1620/tjem.241.319

Cited by 9 publications

(9 citation statements)

References 23 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, DMAb likely increases H-BMD. 4 , 19 Eriksen et al have reviewed the effects of TPTD treatment on hip OP and concluded that TPTD showed positive effect in patients with hip OP. 20 Further, in this study, H-BMD, especially FN-BMD, was greatly increased by DMAb after pretreatment with TPTD.…”

Section: Discussionmentioning

confidence: 99%

Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy

Kamimura

Taguchi²,

Nakamura³

et al. 2018

TCRM

Self Cite

View full text Add to dashboard Cite

BackgroundWhile it is well known that teriparatide (TPTD) increases bone mineral density (BMD) in osteoporotic patients, it is unknown whether TPTD pretreatment affects BMD after denosumab (DMAb) therapy.MethodsFifty-seven patients in TPTD-pretreated group and 35 patients in DMAb-alone group had been further analyzed, all of whom were treated by DMAb for 1.5 years. Vitamin D (400 IU) and Ca (600 mg) supplementation was used in all patients. The BMD of lumbar 1–4 vertebrae (L-BMD), bilateral total hips (H-BMD), and bilateral femoral neck (FN-BMD) was quantified at first visit, and at 4, 8, 12, and 18 months after daily TPTD treatment following four times DMAb treatment.ResultsThere were significant differences in L-BMD (p=0.004) and H-BMD (p=0.026) at baseline between TPTD-pretreated and DMAb-alone groups, although there was no significant difference in FN-BMD between the two groups. The increase of L-BMD by DMAb therapy was less in TPTD-pretreated group than in DMAb-alone group. There was no significant difference in H-BMD, although percent changes of H-BMD tended to be higher in the TPTD-pretreated group than those in the DMAb-alone group. Percent change in FN-BMD at 4 months (p=0.067) and 12 months (p=0.057) tended to be higher in TPTD-pretreated group than in DMAb-alone group. Percent change in FN-BMD at 18 months was significantly higher in TPTD-pretreated group (p=0.004) than in DMAb-alone group.ConclusionThese findings suggest that the pretreatment of TPTD might have enhanced the increase of BMD in cortical bones treated by DMAb. Thus, it is favorable that TPTD can be used for osteoporotic patients who have high fracture risks with cortical bones.

show abstract

Section: Discussionmentioning

confidence: 99%

Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy

Kamimura

Taguchi²,

Nakamura³

et al. 2018

TCRM

Self Cite

View full text Add to dashboard Cite

show abstract

“…The coefficients of variation of the L-BMD and H-BMD measurements were 1.0% and 0.6%, respectively. 13 All TRACP-5b and BAP measurements were performed by SRL Inc. (Tokyo, Japan). Results in Table 1 – 3 were expressed as mean ± SD, and results in Figure 1 were expressed as mean ± standard error (SE).…”

Section: Methodsmentioning

confidence: 99%

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment

Nakamura

Suzuki

Kato

2017

TCRM

Self Cite

View full text Add to dashboard Cite

A worldwide health concern, osteoporosis (OP), increases the risk of bone fracture and results in morbidity. This study examined whether the representative bone absorption marker serum tartrate-resistant acid phosphatase 5b (TRACP-5b) or bone formation marker bone alkaline phosphatase (BAP) could estimate primary OP status and denosumab efficacy in a real-world setting. We retrospectively enrolled 114 female postmenopausal primary OP patients in Japan. Values and percent changes in TRACP-5b, BAP, lumbar 1–4 bone mineral density (L-BMD), and total hip BMD (H-BMD) were assessed before treatment and at 4, 8, and 12 months of therapy to identify the correlations between the percent changes in bone metabolic markers and BMD. We also established two sets of subgroups based on the upper limits of reference values in Japan for serum: TRACP-5b (<420 mU/dL) and (≥420 mU/dL) and BAP (<14.5 µg/L) and (≥14.5 µg/L). Negative correlations were observed for the percent changes of TRACP-5b and H-BMD at 4 months (r=−0.3476) and 8 months (r=−0.3880), for the percent changes of BAP and H-BMD at 8 months (r=−0.3354), and for the percent changes of BAP and L-BMD at 12 months (r=−0.3186). We observed a significant difference between the subgroups for the percent changes of L-BMD at 8 months (p=0.013) and 12 months (p=0.004) in BAP values. These results suggest that TRACP-5b and BAP had negative correlations with BMD, and that BAP represented a useful serum marker to evaluate L-BMD during denosumab therapy for OP.

show abstract

“…Osteoporosis is a systemic disease characterized by decreased bone density and more risk of bone breakage. It is the most famous metabolic bone disease in the adults, especially in postmenopausal women (1) .…”

Section: Introductionmentioning

confidence: 99%

Reliability of Different Mandibular Radio morphometric Indices in Prediction of Osteoporosis and Osteopenia

Youssif

Elshall

2020

ADJ-for Girls

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate the value of quantitative and qualitative mandibular radio morphometric indices, as recorded from panoramic imaging, in prediction and diagnosis of osteoporosis and osteopenia. Materials and methods: Forty postmenopausal women their age between 45 and 65 years previously diagnosed as having osteoporosis as confirmed by DEXA scans were selected. DEXA and Orthopantomogram (OPG) were applied on all the patients. Panoramic mandibular index (PMI), Mental index (MI), gonial index (GI), and mandibular cortical index (MCI) were dignified and matched with the scores obtained from DEXA scan. Results: There was significant correlation between DEXA results with panoramic indices in the normal, osteopenia and osteoporotic groups. Conclusion: By increasing the age and the postmenopausal duration, MCW and PMI decrease, therefore, dentists and dent maxillofacial radiologists could act in a particular manner in early diagnosis of low BMD and help to refer high-danger patients for precise evaluation.

show abstract

Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis

Cited by 9 publications

References 23 publications

Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy

Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment

Reliability of Different Mandibular Radio morphometric Indices in Prediction of Osteoporosis and Osteopenia

Contact Info

Product

Resources

About